In summary, CD44 aptamer may be an effective carrier molecule for targeted delivery of therapeutic agents to the lysosomes of RPE cells to overcome lysosomal inefficiency during oxidative stress in AMD patients. The gene discussed is CD44; the disease is age-related macular degeneration.